<DOC>
	<DOC>NCT01387802</DOC>
	<brief_summary>The current study will assess the real - life effectiveness of adalimumab in the management of Ankylosing Spondylitis (AS) with emphasis on the prevention and management of extra-articular manifestations.</brief_summary>
	<brief_title>Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis, Ankylosing</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
	<criteria>Adult &gt;= 18 years old; Has provided written informed consent allowing the use of their data for the study and providing permission for contact by the study personnel; Active Ankylosing Spondylitis as per the judgment of the treating physician; Inadequate response or non tolerant to current NSAID (Nonsteroidal AntiInflammatory Drug) or DMARD (DiseaseModifying Anti Rheumatic Drug) based treatment for AS Currently participating in another prospective study including controlled clinical trials and observational studies; Patient cannot or will not sign informed consent; Stable disease with adequate tolerance and response to current treatment and no change in treatment is indicated; Previous treatment with antiTNF (Tumor Necrosis Factor) or other biologic agent; Presence of other condition that, in the opinion of the treating physician, prohibits the patient from participating in the study or obscures the assessment of the treatment of AS</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Assessing Effectiveness in Ankylosing Spondylitis</keyword>
</DOC>